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INTRODUCTION
A high incidence of  virologic breakthrough (VBT) that 
results from viral resistance is a major disadvantage of  
lamivudine (LAM) treatment for patients with chronic 
hepatitis B (CHB). Data from a study of  592 patients who 
had undergone four years of  LAM treatment indicated 
that resistance increased from 23% in year 1 to 71% in 
year 4[1,2]. The clinical consequences of  viral resistance 
can be severe, but early studies suggest that median 
HBV DNA and ALT levels continue to improve even as 
resistance develops[3]. LAM is known to have long-term 
therapeutic effects, with well-known resistance and side 
effects. LAM therapy for CHB patients with advanced 
fibrosis significantly reduced the incidence of  hepatic 
decompensation and hepatocellular carcinoma (HCC)[4]. 
In addition, it is becoming increasingly clear that CHB 
management requires a long-term therapy, thus making the 
cost of  treatment an important consideration. The need 
for long-term therapy and the consequent fi nancial burden 
become significant in the economically disadvantaged 
regions of  the world which also happen to be the hyper-
endemic areas for HBV. Furthermore, this cost issue 
presents a serious economic burden for CHB patients 
who immigrated to the US from the hyper-endemic 
regions. One study suggested that upfront LAM therapy 
may be highly cost-effective, assuming that patients who 
develop resistance begin a regimen of  adefovir instead of  
continuing LAM treatment[5]. Our study sought to identify 
the factors associated with VBT in patients on LAM 
therapy and attempted to select a subgroup of  patients 
who may respond well to LAM without developing VBT. 
MATERIALS AND METHODS
Patients
We reviewed the medical records of  208 CHB patients 
who were treated at the Liver Disease Prevention Center, 
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Abstract
AIM: To identify the factors associated with virologic 
breakthrough and to select a subgroup of patients who 
respond well to lamivudine without developing virologic 
breakthrough (VBT). 
METHODS: Of 79 patients who had received lamivudine 
therapy for 9-57 mo, 34 were HBeAg-positive and 
45 were HBeAg-negative, 24 developed virologic 
breakthrough and 55 did not. Clinical and virologic 
factors were compared between the two groups. 
RESULTS: The median duration of therapy was 25 (9-57) 
mo. Virologic breakthrough was defi ned as a > 1 log HBV 
DNA increase following initial suppression. When several 
factors, including gender, duration of infection, baseline 
HBV DNA, and baseline ALT in HBeAg-positive chronic 
hepatitis patients were analyzed by logistic regression, 
the most important predictor of virologic breakthrough 
was the baseline HBV DNA (r 2 = 0.12, P  < 0.05). When 
HBeAg-postitive chronic hepatitis patients were divided 
into two groups by a point of 6.6 log HBV DNA, the 
incidence of virologic breakthough between two groups 
was signifi cantly different.
CONCLUSION: Lamivudine may remain an effective 
fi rst line therapy for those HBeAg-positive patients with a 
baseline HBV DNA < 6.6 log10 copies/mL.
© 2007 WJG. All rights reserved.
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Division of  Gastroenterolgoy and Hepatology at Thomas 
Jefferson University Hospital, Philadelphia from January 
2000 to December 2004. Ninety-seven patients were 
excluded because they were treated with other anti-viral 
agents (excluding interferon) prior to their fi rst visits. Five 
were excluded due to co-infection with Hepatitis C virus. 
We selected individuals from the remaining 106 patients 
who had been on LAM therapy for at least 9 mo (which 
excluded 14 patients) and whose pre-treatment HBV 
DNA was greater than 3 log10 copies/mL (which excluded 
5 patients). Baseline HBeAg status was not available for 
four patients. Four patients who had suboptimal responses 
during the entire treatment period were also excluded from 
the final analysis because of  uncertainty of  classifying 
these patients into either the breakthrough or the non-
breakthrough group. In the end, clinical and laboratory 
data from a total of  79 patients were reviewed. 
Inclusion and exclusion criteria
The inclusion criteria consisted of  the following two 
conditions: (1) Patients had received LAM therapy for at 
least 9 mo; and (2) they had a baseline HBV DNA level 
≥ 3 log10 copies/mL. Patients were excluded if  they had 
previously received anti-HBV therapy (with the exception 
of  interferon therapy), or if  they had hepatitis C virus or 
hepatitis D virus co-infection. 
HBsAg, HBeAg, anti-HBe, and HBV DNA quantifi cation 
All patients had been positive for hepatitis B surface 
antigen (HBsAg) for more than 6 mo. HBeAg/anti-HBe 
and anti-HDV were determined using ELISA (Abbott 
Laboratories, Chicago, IL), and anti-HCV antibodies were 
assayed using a third-generation enzyme immunoassay 
(Abbott Laboratories, North Chicago, IL). Between 
2000 and 2002, a solution hybridization assay (Abbott 
Laboratories, North Chicago, IL) with a lower limit of  
detection (LLOD) of  1.6 pg/mL was used to measure 
HBV DNA levels. These values were converted to copies/
mL by determining 283 000 copies/mL per 1 pg/mL of  
HBV DNA. From 2003 until the present, HBV DNA was 
measured by RT-PCR (Quest Diagnostics, Horsham, PA) 
with a lower limit of  detection of  500 copies/mL. Serial 
dilutions were performed for samples exceeding 5.3 log10 
copies/mL. Values below this cutoff  were assigned a value 
of  1 log10 copies/mL. 
Defi nitions
The initial virologic response was defi ned as HBV DNA 
that was less than 4 log10 copies/mL after 6 mo on therapy, 
and viral suppression was defined as the difference 
between the level of  HBV DNA at baseline and after 6 mo 
of  treatment. Maximal virologic suppression was defi ned 
as the difference in HBV DNA levels between baseline 
and nadir. VBT was defined as > 1 log10 copies increase 
in HBV DNA from nadir on two consecutive occasions 
after an initial virologic response or HBV DNA could be 
detected again after the previous report of  “under the 
detection limit”. Suboptimal responders were defined as 
patients whose initial virologic response was less than 2 log 
during the entire period of  treatment.
Determination of HBV genotype, antiviral resistance,
precore mutant, and core promotor mutant 
HBV DNA was extracted using the QIAamp DNA 
Blood Mini Kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. The presence of  HBV DNA 
polymerase gene mutations was determined using the 
InnoLiPA DR2 line probe assay (InnoGenetics, Ghent, 
Belgium) according to the manufacturer’s instructions. Line 
probe results were confi rmed by bi-directional automated 
sequencing at the DNA sequencing core facility (Thomas 
Jefferson University’s nucleic acid facility, Philadelphia, PA) 
using the standard protocol for the Applied Biosystems 
DNA Sequencer 377 (Perkin Elmer Corp., Foster City, 
CA). This amplicon covers domains A, B, C, D, and E of  
the reverse transcriptase region of  the HBV polymerase. 
The PCR protocol and primers for the surface/polymerase 
gene and core promotor/precore region used in this study 
were described previously[6].
Statistical analysis 
Statistical testing was performed using SPSS version 13.0 
(SPSS Inc., Chicago IL). Results were expressed as mean 
± SD or median (minimum-maximum). HBV DNA levels 
were logarithmically transformed for analysis. Continuous 
variables were compared using the two-tailed student’s 
t-test, and categorical data were compared using the two-
tailed χ2 test. Factors associated with an initial virologic 
response and LAM resistance were analyzed by univariate 
analysis. Clinical, biochemical and virologic factors that 
could influence LAM resistance, including gender, route 
of  infection, baseline ALT level, baseline HBV DNA level, 
were analyzed by binary logistic regression. The cumulative 
probability of  lamivudine resistance was estimated by 
Kaplan-Meier analysis. P < 0.05 was considered statistically 
signifi cant.
RESULTS
Baseline characteristics of patients prior to beginning
lamivudine treatment
Seventy-nine patients (54 males) met eligibility criteria. 
All were Asian Americans, with a mean age of  47 ± 12 
years. Thirty-seven (45%) had been infected at birth by 
vertical transmission from their mothers. Twenty-four 
patients (30%) had liver cirrhosis and two (2%) had liver 
cancer prior to starting LAM therapy. The mean duration 
of  therapy was 26 ± 10 mo. At baseline, the ALT was 66 
(11-3395) IU/L and the mean log HBV DNA level was 
6.0 ± 1.6. The baseline HBV DNA level in the 34 HBeAg-
positive patients was 6.6 ± 1.5, and the baseline DNA 
level in the 45 HBeAg-negative patients was 5.6 ± 1.5 
log10 copies/mL. Treatment was initiated if  HBV DNA 
levels were ≥ 3 log10 copies/mL. Eighteen patients had 
HBV DNA levels between 3 and 5 log10 copies/mL. Based 
on earlier observations of  317 CHB patients[7], normal 
pre-therapy ALT was not considered a contraindication 
for beginning antiviral therapy in certain patients. These 
included patients who had normal ALT levels, high viral 
DNA, and a strong family history of  HCC or patients 
who had had previous ALT spikes but whose ALT levels 
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were normal at the beginning of  the study. All baseline 
characteristics except HBV DNA level were similar 
between the VBT and non-VBT groups. Only ALT level 
was shown as mean ± SE (Table 1). 
Response to lamivudine treatment 
In HBeAg-positive patients (n = 34), the mean log reduction 
(copies/mL) in HBV DNA from baseline was 4.6 ± 1.4, 3.7 
± 2.4 and 2.7 ± 3.0 at 6 mo, 12 mo and 24 mo, respectively. 
The less reduction in two years may be due to VBT in 
some patients. As shown in Table 2, initial viral suppression 
was 4.2 ± 2.0 and 4.3 ± 1.5 in VBT and non-VBT groups, 
respectively. The maximal viral suppression was 4.8 ± 1.7 
and 4.6 ± 1.2 in VBT and non-VBT groups, respectively. 
Eighty percent of  patients showed an initial anti-viral 
response at 6 mo post-treatment. HBeAg loss rate was 18, 
26, and 29% at 1, 2, and 3 years, respectively. Excluding 
individuals with normal or absent ALT levels at baseline, 
ALT normalization was observed in 90% and 96% of  
patients after 6 mo and 12 mo, respectively. The mean time 
for VBT detection was 21 (9-36) mo. There was no viral or 
biochemical variable with a significant difference between 
VBT and non-VBT groups.
In HBeAg-negative patients (n = 45), the mean log 
reduction (copies/mL) in HBV DNA from baseline was 
3.2 ± 2.0 at 6 mo, 4.2 ± 1.9 at one year, and 3.1 ± 3.0 at 
two years. Initial viral suppression was 2.8 ± 2.5 and 3.4 
± 1.9 in VBT and non-VBT groups, respectively. Maximal 
suppression was 4.3 ± 1.7 and 4.3 ± 1.6 in VBT and non-
VBT groups, respectively. Eighty-one percent of  patients 
showed an initial antiviral response at 6 mo post-treatment. 
Excluding individuals with normal or absent ALT levels 
at baseline, ALT normalization was observed in 84% and 
82% of  patients after 6 mo and 12 mo, respectively. The 
mean time for VBT detection was 22 (9-36) mo. Also, 
there was no viral or biochemical variable with a signifi cant 
difference between VBT and non-VBT groups. 
HBV genotype, precore mutant, and core promotor mutant 
HBV DNA sequences were examined in nine patients’ sera 
that were collected at the time of  baseline and VBT. Six 
patients without VBT were also examined as controls. The 
samples from 15 patients were investigated for genotype, 
precore mutant, and core promoter mutant. As shown in 
Table 3, YMDD mutants were observed in six of  the nine 
individuals in the VBT group and none were observed in 
the non-VBT group (67% vs 0%, P < 0.01). All patients 
had HBV genotype C. The frequency of  precore and core 
promotor variants did not differ signifi cantly between VBT 
and non-VBT groups. 
Patient 6 in the VBT group had a precore mutation in 
the 1896 position and was HBeAg-positive (Table 3). Pa-
tients 3 and 8 also had smaller A peaks than G peaks at the 
1896 position, but were classifi ed as wild-type (Table 3).
VBT relative to baseline HBV DNA levels
When all factors, including gender, duration of  infection, 
baseline HBV DNA, HBV DNA at the 6th month of  
treatment, and baseline ALT in HBeAg-positive CHB 
patients were analyzed by logistic regression, the most 
important factor associated with VBT was only baseline 
HBV DNA level (r2 = 0.12, P < 0.05) .
When HBeAg-positive CHB patients were divided into 
two groups by the point of  6.6 log HBV DNA level: one 
group > 6.6 log HBV DNA; and other group ≤ 6.6 log 
HBV DNA, there was a signifi cant difference between two 
groups in terms of  VBT rate (P < 0.05). We also compared 
the cumulative VBT rate between these two groups 
according to the treatment duration with Kaplan-Meier 
analysis. The VBT percentage in HBeAg-positive hepatitis 
patients with HBV DNA levels ≤ 6.6 log10 (n = 15) was 
6.7%, 18%, and 39% at 1, 2, and 3 years, respectively, while 
that in patients with HBV DNA levels > 6.6 log10 (n = 17) 
was 19%, 45%, and 88% at 1, 2, and 3 years, respectively 
(P = 0.061) (Figure 1). 
The next important factor associated with VBT was 
HBV DNA at the 6th month of  treatment, but it did not 
show a significant correlation with VBT. In HBeAg-
negative patients, no relationship between the VBT rate 
and HBV DNA level was observed.
DISCUSSION
Our study demonstrated that patients with lower HBV 
DNA levels had less VBT with LAM therapy. Other 
predictors of  LAM-resistant mutations include male 
gender, Asian ethnicity, higher baseline HBV DNA, longer 
duration of  lamivudine treatment, and higher BMI[2]. Our 
study clearly showed that the baseline HBV DNA level is 
the most signifi cant predictor. However, it is true that the 
number of  study subjects was relatively small (n = 79) and 
the median duration of  follow-up was about 40 mo.
But, the findings of  our study are contradictory to 
the observation of  the Taiwanese study[8]. They reported 
that HBeAg status, HBV DNA, ALT levels and treatment 
duration were the major determinants for the YMDD 
mutation during lamivudine therapy. The most important 
difference between two studies is what they observed. We 
observed VBT, but they observed the genotypic resistance. 
Besides, there were several differences between two 
studies, such as study designs and the test for HBV DNA.
Table 1  Baseline characteristics of patients (mean ± SD)
All patients
(n  = 79)
Breakthrough
(n  = 24)
Non-breakthrough
(n  = 55)
Age (yr)    47 ± 12    47 ± 13    47 ± 11
Female (%)    32    29    33
Family history of CHB (%)    47    46    55
ALT (IU/L)  149 ± 44    98 ± 20  171 ± 63
Total bilirubin (mg/dL)   1.1 ± 1.1   1.3 ± 1.4   1.0 ± 0.9
Albumin (g/dL)   4.4 ± 0.4   4.2 ± 0.5   4.3 ± 0.4
(INR) 1.07 ± 0.12 1.09 ± 0.15 1.06 ± 0.08
Cirrhosis (%)    30    36    24
HBeAg-positive (%)    43    56    36
HBV DNA log10 
copies/mLa
  6.0 ± 1.6   6.6 ± 1.5   5.7 ± 1.5
Mean duration of 
lamivudine treatment (mo)
   26 ± 10    29 ± 11    25 ± 10
3 log < HBV DNA < 5 log (%)    19      3    16
HBV DNA ≥ 5 log (%)    60    21    39
aP < 0.05 breakthrough vs non-breakthrough group INR: International 
normalized ratio..
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When the study criteria were set up, AGA (American 
Gastroenterology Association) expert panel recommendations 
were followed; HBeAg-positive patients were individuals with 
HBV DNA > 5 log10 copies/mL, while HBeAg-negative 
patients were individuals with HBV DNA > 4 log10 copies/
mL. In this study, a lower HBV DNA cutoff, above 3 log, 
was used for starting antiviral treatment. Although we did 
not know the recent Taiwanese data when we started to treat 
our patients, but it shows that higher baseline serum DNA 
levels are associated with increased risk of  HCC and liver 
cirrhosis independent of  serum ALT level[9]. The AGA panel 
specifi es that ALT levels should be abnormal, but this is not 
always helpful in determining who should be treated[10]. ALT 
levels do not serve as a good indicator of  liver cirrhosis. 
In addition, revision of  the normal limits for ALT levels 
was recommended in patients with chronic HCV infection 
or nonalcoholic fatty liver disease (NAFLD) since current 
standards for normal were defined using the populations 
that included individuals with subclinical disease[11,12]. Some 
patients experienced disease progression during follow-up 
because they had normal ALT levels and were not treated 
earlier. Thus, early antiviral treatment may be benefi cial to 
reduce HBV DNA levels, HCC risk, and the frequency of  
liver transplantations[13]. LAM can reduce serum HBV DNA 
levels and normalize ALT level in cirrhotic patients[14,15].
As shown in Table 1, we noted that HBeAg-negative 
CHB have lesser LAM resistance than HBeAg-positive 
CHB, which is in agreement with previous studies[16,17].
We conducted genotypic resistance analysis on 15 pa-
tients who had serum samples harvested upon viral break-
through or at the end of  follow-up. Genotypic resistance 
occurred only in the VBT group and was not observed in 
the non-VBT group. However, three patients in the VBT 
group, and fi ve in the non-VBT group had the wild-type. 
The most plausible explanation for the disparity between 
phenotypic and genotypic resistance is medication non-
compliance. Possible solutions for this problem, like pill 
counts and nurse monitoring, were beyond the scope of  
our study. A blip in viral numbers is another potential ex-
planation for the presence of  wild-type virus in the VBT 
patients. The InnoLiPa assay could be used to defi ne the 
mixed strains in six patients from the VBT group. When 
Table 2  Response to lamivudine before breakthrough (mean ± SD)
        HBeAg-positive hepatitis (n  = 34)  HbeAg-negative hepatitis (n  = 45)
All patients 
(n  = 34)
BT 
(n  = 14)
No BT 
(n  = 20)
All patients 
(n  = 45)
BT 
(n  = 10)
No BT
(n  = 35)
Max suppression (log10 copies/mL) 4.7 ± 1.4 4.8 ± 1.7 4.6 ± 1.2 4.3 ± 1.6 4.3 ± 1.7 4.3 ± 1.6
Initial suppression (log10 copies/mL) 4.2 ± 1.7 4.2 ± 2.0 4.3 ± 1.5 3.3 ± 2.1 2.8 ± 2.5 3.4 ± 1.9
Patients with IVR (%) 80 75 83 81 67 85
Patients at 6 mo biochemical response (%) 90 82 94 84 86 83
Patients at 12 mo biochemical response (%) 96 100 93 82 80 82
Time to fi rst detection of BT -  26 ± 10 - -  32 ± 12 -
BT: Breakthrough; Max suppression: Maximal virologic suppression; Initial suppression: Initial virologic suppression; IVR: Initial virologic response at 6 mo; 
Biochemical response: ALT normalization.
Table 3  HBV genotypes, variants, and lamivudine-resistant mutants
                Patients with VBT                                                                                                       During BT





1 F + C 19   90 - 5.4 Wild TA M I/V
2 M + C 18   29 - 3 Stop TA L I/V
3 F + C 12   12 + 6.8 Wild AG L M
4 M + C 18   44 + 8.3 Wild TA M I/V
5 M + C 36 NA + 5.2 Wild TA M I/V
6 F + C 21   42 + 5.7 Wild AG L M
7 M + C 27   24 + 6.6 Stop TA M I/V
8 F + C 21 NA + 6.7 Wild AG L M
9 F + C 30 108 + 6.7 Wild TA M I/V
                  Patients without VBT                                                                                                 End of follow-up





1 M - C   9 28 + 4.6 Wild TA L M
2 M - C 30 NA + 5.4 Wild TA L M
3 M - C 32 12 - 1 UD UD L M
4 M - C 27 NA + 1 Wild TA L M
5 M - C 36 42 - 1 UD UD L M
6 M - C 24 24 + 1 Wild TA UD UD
PC: Precore mutants; CP: Core promotor mutants; SR: Suboptimal response; NA: Not available; UD: Undetectable; LAM: Lamivudine; BT: Breakthrough; VBT: 
Virologic breakthrough.
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HBV DNA ≤ 6.6 log and limited financial means, we 
conclude that LAM remains an affordable and effective 
therapy.
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Lamivudine is the fi rst FDA-approved oral antiviral agents for chronic hepatitis B 
(CHB) with 10 years experience of safety and effi cacy. It was recently excluded 
from the 1st line drugs in 2007 AASLD practice guideline because of its high rate of 
drug resistance. We investigated the factors associated with virologic breakthrough 
in patients on lamivudine therapy and identified a subgroup of patients who 
responded well to lamivudine without developing virologic breakthrough. Therefore, 
we believe that for this subgroup of CHB patients, lamivudine may still remain the 
most cost-effective drug among 4 currently available oral anti-HBV drugs. 
Research frontiers
Other predictors of lamivudine resistance include male gender, Asian ethnicity, 
higher baseline HBV DNA, long duration of lamivudine treatment, and higher BMI.
Innovations and breakthroughs
Our study clearly showed that the baseline HBV DNA level is the most signifi cant 
predictor for virologic breakthrough and identifi ed the discriminating number as 6.6 
log10 HBV DNA. 
Applications
Physicians can apply this knowledge to predict lamivudine resistance and may 
start lamivudine for this group of patients who present with baseline HBV DNA 
level lower than 6.6 log.
Terminology
Virologic breakthrough: > 1 log10 copies increase in HBV DNA from nadir on two 
consecutive occasions after an initial virologic response.
Peer review
The authors investigated several clinical, biochemical and virologic factors, 
including gender, route of infection, duration of infection, baseline HBV DNA 
level, baseline ALT level, and other factors in HBeAg-positive chronic hepatitis 
B patients. The study is well conducted and the results indicate that the most 
important predictor of virologic breakthrough is the baseline HBV DNA. 
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Upper curve: HBV DNA > 6.6 log c/mL
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+: Censored data
Duration of lamivudine treatment (mo)
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Months                         0        12        24        36
HBV DNA > 6.6 log      14        14          6          3
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